Andrew Brookes | Image Source | Getty Images
The Food and Drug Administration will make a decision on whether to fully approve Eisai‘s and Biogen‘s Alzheimer’s treatment Leqembi by July 6, the companies announced on Monday.
Leqembi is an antibody treatment that targets brain plaque associated with…
Read Full Article Here CNBC